SUMMARY
Margaret M. Redfield, M.D., is a cardiologist and researcher who primarily focuses on heart failure, particularly heart failure with preserved ejection fraction (HFpEF) and pulmonary hypertension related to left heart disease. Dr. Redfield's research aims to elucidate the epidemiology, pathophysiology and therapeutic strategies for these conditions.
Dr. Redfield's work is highly translational. She employs mechanistic studies in human subjects, human tissue and animal models to advance the understanding of cardiovascular diseases. Her extensive experience includes leading multicenter clinical trials, biomarker studies, and innovative therapeutic approaches in patients and preclinical animal models.
Focus areas
- HFpEF. Dr. Redfield established the epidemiology of HFpEF and investigates its underlying mechanisms, focusing on diastolic dysfunction, coronary microvascular dysfunction and myocardial fibrosis. Her work includes epidemiological studies and clinical trials to develop targeted therapies for HFpEF.
- Pulmonary hypertension in left heart disease. Dr. Redfield's work has helped to better recognize and diagnose pulmonary hypertension in the context of HFpEF, shaping diagnostic guidelines and exploring the pathophysiological mechanisms through clinical and preclinical studies.
- Novel therapeutics. Dr. Redfield leads and participates in multicenter randomized clinical trials to test new therapeutic strategies for HFpEF and other heart failure conditions. This includes studies on phosphodiesterase-5 inhibitors, natriuretic peptides and other approaches to modifying NO-cGMP signaling.
- Biomarker discovery. Dr. Redfield's research includes the use of biomarkers to characterize heart failure phenotypes and predict outcomes, contributing to personalized medicine approaches in cardiology.
- Cardiorenal interactions. Dr. Redfield's work explores the interplay between cardiac and renal function in heart failure to uncover mechanisms and develop treatments that address these complex interactions.
Significance to patient care
Dr. Redfield's research advances have led to better approaches to diagnose and treat HFpEF and pulmonary hypertension in left heart disease. Dr. Redfield's work on biomarkers helps healthcare professionals safely customize effective treatments to each patient.
Professional highlights
- Senior editorial adviser, Journal of the American College of Cardiology Heart Failure, 2022-present.
- National Heart, Lung, and Blood Institute:
- Member, Steering Committee, HeartShare Study, 2021-present.
- Member, Steering Committee, Heart Failure Clinical Research Network, 2006-present.
- Chair, Clinical Trial Review Study Section, 2013-2014.
- Member, Clinical Trial Review Study Section, 2008-2013.
- Co-director, Cardiorenal Laboratory, Mayo Clinic, 1995-present.
- American Heart Association (AHA)-American College of Cardiology (ACC):
- ACC Distinguished Scientist Award (Translational Domain), 2023.
- AHA Population Science Prize, 2019.
- Member, Writing Group: American Heart Association Science Advisory on Pulmonary Hypertension in HFpEF, 2021-2022.
- World's Top 2% Scientists, Stanford University, 2021.
- Chair, Division of Circulatory Failure, Mayo Clinic, Rochester, Minnesota, 2016-2021.
- Distinguished Investigator Award, Mayo Clinic, 2016.
- Director, Section of Circulatory Failure, Mayo Clinic, Rochester, Minnesota, 2012-2016.
- Walter and Leonore Annenberg Professor in Cardiology and Critical Care, Mayo Clinic, 2014.